pI: 10.5143 |
Length (AA): 130 |
MW (Da): 15337 |
Paralog Number:
0
Signal peptide: N | GPI Anchor: | Predicted trans-membrane segments: 0
Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable
Modbase 3D models:
There is 1 model calculated for this protein. More info on
this model, including the
model itself is available at:
Modbase
Target Beg | Target End | Template | Template Beg | Template End | Identity | Evalue | Model Score | MPQS | zDope |
---|---|---|---|---|---|---|---|---|---|
5 | 177 | 3iij (A) | 0 | 169 | 51.00 | 0 | 1 | 1.7334 | -1.84 |
Help me make sense of these data.
A more detailed description of these scores is available at the Modbase Model Evaluation Help Pages, and in the papers referenced therein.
PDB Structures:
Ortholog group members (OG5_127564)
Species | Accession | Gene Product |
---|---|---|
Arabidopsis thaliana | AT5G60340 | adenylate kinase isoenzyme 6 |
Arabidopsis thaliana | AT5G60335 | thioesterase-like protein |
Babesia bovis | BBOV_II007510 | conserved hypothetical protein |
Brugia malayi | Bm1_24715 | Hypothetical UPF0101 protein E02H1.6 in chromosome II, putative |
Candida albicans | CaO19.6074 | oxidative stress |
Candida albicans | CaO19.13495 | oxidative stress |
Caenorhabditis elegans | CELE_E02H1.6 | Protein E02H1.6 |
Cryptosporidium hominis | Chro.30373 | protein ad-004 |
Cryptosporidium parvum | cgd3_3270 | possible nucleotide kinase related to CMP and AMP kinases |
Dictyostelium discoideum | DDB_G0278493 | hypothetical protein |
Drosophila melanogaster | Dmel_CG8816 | Adenylate kinase 6 |
Echinococcus granulosus | EgrG_000855050 | TAF9 RNA polymerase II TATA box binding protein |
Entamoeba histolytica | EHI_001120 | hypothetical protein, conserved |
Echinococcus multilocularis | EmuJ_000855050 | TAF9 RNA polymerase II, TATA box binding protein |
Giardia lamblia | GL50803_17258 | Hemoglobin and proliferation regulated protein |
Homo sapiens | ENSG00000085231 | adenylate kinase 6 |
Leishmania braziliensis | LbrM.30.1840 | hypothetical protein, conserved |
Leishmania donovani | LdBPK_301880.1 | Adenylate kinase, nuclear |
Leishmania infantum | LinJ.30.1880 | hypothetical protein, conserved |
Leishmania major | LmjF.30.1890 | hypothetical protein, conserved |
Leishmania mexicana | LmxM.29.1890 | hypothetical protein, conserved |
Loa Loa (eye worm) | LOAG_09515 | TATA box binding protein (TBP)-associated factor |
Mus musculus | ENSMUSG00000078941 | adenylate kinase isoenzyme 6 |
Neospora caninum | NCLIV_033190 | UPF0101 protein CGI-137, putative |
Oryza sativa | 4343011 | Os07g0412400 |
Onchocerca volvulus | OVOC11249 | Adenylate kinase isoenzyme 6 homolog |
Plasmodium berghei | PBANKA_0202800 | adenylate kinase-like protein 1, putative |
Plasmodium falciparum | PF3D7_0110900 | adenylate kinase-like protein 1 |
Plasmodium knowlesi | PKNH_0202600 | adenylate kinase-like protein 1, putative |
Plasmodium vivax | PVX_081255 | adenylate kinase-like protein 1, putative |
Plasmodium yoelii | PY07323 | protein ad-004 |
Saccharomyces cerevisiae | YDL166C | Fap7p |
Schistosoma japonicum | Sjp_0039950 | ko:K03133 transcription initiation factor TFIID subunit D7, putative |
Schistosoma mansoni | Smp_050570 | hypothetical protein |
Schmidtea mediterranea | mk4.029817.00 | Adenylate kinase isoenzyme 6 |
Schmidtea mediterranea | mk4.000011.14 | Adenylate kinase isoenzyme 6 |
Trypanosoma brucei gambiense | Tbg972.6.3000 | hypothetical protein, conserved |
Trypanosoma brucei | Tb927.6.3210 | Adenylate kinase, nuclear |
Trypanosoma cruzi | TcCLB.509171.47 | Adenylate kinase, nuclear |
Trypanosoma cruzi | TcCLB.507023.280 | Adenylate kinase, nuclear |
Toxoplasma gondii | TGME49_233400 | TAF9 RNA polymerase II, TATA box binding protein (TBP)-associated factor isoform 2 family protein |
Theileria parva | TP02_0203 | hypothetical protein, conserved |
Trichomonas vaginalis | TVAG_426750 | protein ad-004, putative |
Gene/Ortholog | Organism | Phenotype | Source Study |
---|---|---|---|
Tb927.6.3210 | Trypanosoma brucei | no significant loss or gain of fitness in bloodstream forms (3 days) | alsford |
Tb927.6.3210 | Trypanosoma brucei | no significant loss or gain of fitness in bloodstream forms (6 days) | alsford |
Tb927.6.3210 | Trypanosoma brucei | no significant loss or gain of fitness in procyclic forms | alsford |
Tb927.6.3210 | Trypanosoma brucei | no significant loss or gain of fitness in differentiation of procyclic to bloodstream forms | alsford |
CELE_E02H1.6 | Caenorhabditis elegans | larval arrest | wormbase |
CELE_E02H1.6 | Caenorhabditis elegans | slow growth | wormbase |
YDL166C | Saccharomyces cerevisiae | inviable | yeastgenome |
TGME49_233400 | Toxoplasma gondii | Probably essential | sidik |
keio | Systematic single-gene knock-out mutants of E. coli K12 | The Keio Collection |
wormbase | C. elegans RNAi experiments | WormBase web site, http://www.wormbase.org, release WS170 |
yeastgenome | Systematic deletion of yeast genes | Saccharomyces Genome Database |
blattner | Systematic mutagenesis of the E. coli (MG1655) genome | J Bacteriol 2004, 186:4921-4930 |
shigen | Profiling of E. coli Chromosome (PEC) | National Institute of Genetics, Japan |
neb | C. elegans RNAi phenotypes | Data obtained from Wormbase WS150, curated by K. Chaudary and T. Carlow, New England Biolabs |
gerdes | Experimental determination and system-level analysis of essential genes in E. coli MG1655 | Gerdes et al., J Bacteriol. 2003 185:5673-84 |
alsford | High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome | Genome Res 2011, 21:915-924 |
nmpdr | Genome-scale essentiality datasets from published studies (M. tuberculosis) | National Microbial Pathogen Data Resource |
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please contact us.